April 3rd 2024
In an interview with Targeted Oncology, Yanghee Woo, MD, discussed some factors to consider when choosing between CROSS and FLOT for gastreoesophageal junction adenocarcinoma treatment.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Trastuzumab Deruxtecan Extends Overall Survival in HER2+ Advanced Gastric/GEJ Cancer
January 20th 2022Updated survival results from the phase 2 DESTINY-Gastric01 trial reveal the survival benefit of trastuzumab deruxtecan HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.
Read More
Evorpacept Pairs Well With Anticancer Regimens Plus Chemotherapy to Elicit Responses in Solid Tumors
November 10th 2021The novel checkpoint inhibitor, evorpacept induced responses in patients with head and neck squamous cell carcinoma and gastric cancer when used in combination with anticancer therapy and chemotherapy in a phase 1b study.
Read More
Data from the phase 3 CheckMate-649 trial showed that the combination therapy of nivolumab and chemotherapy showed a sustained survival benefit in patients with advanced gastric, gastroesophageal junction (GEJ), or esophageal cancer, in contrast to the combination of nivolumab and ipilimumab.
Read More
Survival Benefit in Frontline Esophageal Squamous Cell Carcinoma Seen With Toripalimab/Chemo Combo
September 17th 2021In patients with advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 expression, the addition of toripalimab to platinum-based chemotherapy demonstrated significantly improved survival outcomes.
Read More
Limited Clinical Activity in Second-Line Gastric/GEJ Cancer Seen With Linagliptin/Atezolizumab Combo
September 16th 2021Limited responses as a second-line treatment for patients with locally advanced or metastatic gastric or gastroesophageal junction cancer were seen with Linagliptin plus atezolizumab.
Read More
Pembrolizumab Withdrawn From US Market as Option For Third-Line Gastric or GEJ Adenocarcinoma
July 6th 2021Pembrolizumab has been voluntarily withdrawn from the North American market as a treatment option for patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Read More
Paclitaxel and GSK2636771 Combo Shows Benefit in Certain Patients with Gastric Cancer
July 2nd 2021The combination of paclitaxel and GSK2636771 showed encouraging antitumor activity and a manageable toxicity profile and in patients with PTEN-deficient advanced gastric cancer who progressed after first line chemotherapy.
Read More
ODAC Panel Approves 4 of 6 Anti–PD-1/PD-L1 Drugs in Accelerated Approval Program
June 16th 2021An FDA Oncologic Drugs Advisory Committee meeting resulted in continued approval for 4 of 6 indications that were discussed, although all 6 indications did not demonstrate clinical benefit in confirmatory studies. The meeting, held April 27-29, evaluated anti–PD-1/PD-L1 drugs that received accelerated approvals through the FDA’s accelerated approval program, a nearly 30-year-old initiative to expedite the approval process.
Read More
Roundtable Discussion: Catenacci Compares Frontline Treatment for Patients With Gastric Cancer
May 20th 2021The treatment landscape for gastric cancer is evolving. The use of biomarkers and implementation of testing to improve outcome later on in the course of treatment are being more important.
Read More
The FDA has granted accelerated approval to pembrolizumab plus trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction cancer.
Read More
FDA’s ODAC Votes Against Continuation of Pembrolizumab Third-Line Indication in Gastric/GEJ Cancer
April 29th 2021The FDA’s Oncologic Drugs Advisory Committee has voted 6 to 2 against the continued approval of pembrolizumab as indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 who experienced disease progression on or after 2 or more prior lines of therapy, including fluoropyrimidine- and platinum-containing chemotherapy and, if appropriate, HER2-targeted therapy.
Read More
FDA Approves Nivolumab Plus Chemotherapy as 1L Therapy for Advanced or Metastatic Gastric Cancer
April 16th 2021The FDA has approved nivolumab in combination with certain chemotherapies for the initial treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
Read More
HER2-Expressing Gastric Cancer Cells Respond to Treatment With Trastuzumab Deruxtecan
April 10th 2021For the treatment of patients with HER2-amplified gastric cancers in addition to those with HER2 moderate-, low-, and non-expressing disease, trastuzumab deruxtecan has shown to be an effective therapeutic option.
Read More
Frontline Bemarituzumab Doublet Prolongs Survival in Advanced FGFR2b+ Gastric/GEJ Cancer
January 16th 2021In the frontline setting of FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma, the combination of bemarituzumab combined with mFOLFOX6 achieved a 56% reduction in the risk of disease progression or death compared with placebo.
Read More